Pure Red Cell Aplasia in Patients With Chronic Kidney Disease and in Use of Epoetin Alfa
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 531 participants.
Also called NCT02648126
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose diagnostic
- Phase
- Phase 4
- Enrolled
- 531 participants
- Sponsor
- The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
- Registry
-
NCT02648126
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT02648126. Allocation not applicable; no masking; primary purpose diagnostic. Start 2015-11 (registry gives no type); primary completion 2017-07 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Pure Red Cell Aplasia in Patients With Chronic Kidney Disease and in Use of Epoetin Alfa
- Condition
- Red-Cell Aplasia, Pure
- Condition
- Renal Insufficiency, Chronic
- Intervention (Procedure)
- Pure Red Cell Aplasia diagnostic confirmation
- Lead sponsor
- The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
Record details
- Record id
cardio:ct-nct02648126- Content hash
684b5859d4109107d0819ea9501ab0d4bddc5347bcf10794cde60d22c024bf81